VRPX Stock - Why Is Virpax Pharmaceuticals (VRPX) Stock Up 98% Today?

Source: Shutterstock / PopTika

Virpax Pharmaceuticals (NASDAQ:VRPX) stock is rocketing higher on Wednesday after the preclinical-stage pharmaceutical company announced positive results from a swine model pilot study.

Virpax Pharmaceuticals has released results from its swine model study of Probudur. This is a treatment candidate to assist in immediate and long-term pain management at wound sites.

Virpax Pharmaceuticals is developing Probudur as a replacement for opioids. The swine model study resulted in it injecting four pigs with the treatment. The results were positive, with all four being receptive to the drug.

Virpax Pharmaceuticals also noted that the results showed that Probudur was effective at long-term release. That includes up to six days of pain relief. This confirms its desire to create a treatment with a slow release time.

What’s Next for VRPX Stock?

Here’s what Virpax Pharmaceuticals CEO Gerald Bruce has planned for the company:

“With our agreement to negotiate additional funding from our new institutional investor, and remaining necessary studies underway, we continue to target the end of the year for filing our Investigational New Drug Application (IND) for Probudur.”

VRPX stock is up 98.4% as of Wednesday, with more than 103 million shares traded. That’s well above its daily average trading volume of about 2.9 million shares.

We have more of the most recent stock market stories worth reading about on Wednesday!

InvestorPlace is home to all of the hottest stock market news today! That includes what’s going on with shares of Longeveron (NASDAQ:LGVN) stock, Tesla (NASDAQ:TSLA) stock and Intuit (NASDAQ:INTU) stock today. All of this news is ready at the links below!

More Wednesday Stock Market News

On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.

Read More: Penny Stocks — How to Profit Without Getting Scammed

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.